NCT06667999 The Intensive Care Platform Trial
| NCT ID | NCT06667999 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Anders Perner |
| Condition | Intensive Care Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2025-06-26 |
| Primary Completion | 2035-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 10,000 participants in total. It began in 2025-06-26 with a primary completion date of 2035-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Among critically ill patients, many die, and many of the survivors and their family members struggle for years with reduced quality of life. Critically ill patients are treated in intensive care units (ICUs). Here, they receive life support, e.g., mechanical ventilation and advanced support of the circulation (heart and blood vessels) and kidneys. In addition, ICU patients receive many other treatments. It is, however, uncertain if all the treatments provide value for the patients. The desirable effects of many treatments are uncertain, and some may be wasteful or even harmful. Clinical trials are necessary to validly assess the desirable and undesirable effects of different treatments. However, conventional clinical trials have limitations: * They typically only assess a single question related to a single comparison of treatments at a time. * They are often not very flexible, including with regards to the number of participants needed, and this increases the risk that a trial will end up as inconclusive. * There is no or limited re-use or sharing of infrastructure across trials, leading to duplicate work and resource use. * Trial participants do usually not benefit from the obtained knowledge before the trial concludes. * Involvement of patients, family members, and other stakeholders is typically limited, which may decrease the relevance of the questions addressed. With the Intensive Care Platform Trial (INCEPT), we aim to tackle these challenges by establishing a flexible platform trial that continuously learns from the obtained results. The platform trial may run forever with simultaneous and continuous assessment of many treatments. INCEPT will continuously learn from the accrued data and use these to improve the treatment of both participating and future patients. With INCEPT, we are also building a framework for thorough and extensive involvement of key stakeholders, including patients and family members. INCEPT will improve the way clinical trials are done and increase the probabilities that treatments are improved. This will: * Directly improve outcomes for ICU patients. * Relieve a strained healthcare system by discarding inefficient or harmful treatments. * Ensure that new treatments are beneficial or cost-effective before implementation. * Lower the costs and burdens of assessing more treatments in the critically ill.
Eligibility Criteria
The general eligibility criteria below apply to INCEPT as a whole and thus to all domains. Domains may impose domain-specific eligibility criteria that restrict the population eligible for that domain further, but domains are not allowed to broaden the general eligibility criteria. Domain-specific eligibility criteria always apply to all arms in a domain. PLATFORM INCLUSION CRITERIA: * Adult patient (≥18 years old) acutely admitted to the ICU. This includes ICU admissions after emergency surgery, unplanned ICU admissions after elective surgery, and prolonged ICU admissions due to complications after elective surgery (i.e., admissions occurring or being prolonged due to an unexpected, worsened condition, but excluding planned ICU admissions after elective surgery without clinical deterioration). * Eligible for at least one active domain. PLATFORM EXCLUSION CRITERIA: * Informed consent following inclusion expected to be unobtainable (e.g., known previous objections to participation). * Patient is under coercive measures (e.g., ongoing involuntary hospital stay or under the jurisdiction of correctional authorities). Patients who have previously been included in INCEPT may only be included again during new ICU admissions but may only be randomised to domains in which they have not previously been randomised. DOMAIN-SPECIFIC ELIGIBLE CRITERIA: Each domain may have additional eligibility criteria. Refer to the study website for more information (www.incept.dk).
Contact & Investigator
Anders Perner, Professor
STUDY CHAIR
Copenhagen University Hospital - Rigshospitalet, Department of Intensive Care
Frequently Asked Questions
Who can join the NCT06667999 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intensive Care Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06667999 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06667999 currently recruiting?
Yes, NCT06667999 is actively recruiting participants. Contact the research team at anders.perner@regionh.dk for enrollment information.
Where is the NCT06667999 trial being conducted?
This trial is being conducted at Aabenraa, Denmark, Aalborg, Denmark, Aarhus, Denmark, Aarhus, Denmark and 11 additional locations.
Who is sponsoring the NCT06667999 clinical trial?
NCT06667999 is sponsored by Anders Perner. The principal investigator is Anders Perner, Professor at Copenhagen University Hospital - Rigshospitalet, Department of Intensive Care. The trial plans to enroll 10,000 participants.